Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.
Pharmaceutical companies are increasingly turning to companion diagnostic tests to determine whether a drug is suitable for a given patient.
Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.
The Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. mRNA are equally as important.
Biodesix: advances in personlized medicine for lung cancer, Science Daily article
Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.
Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)
Veristrat from Biodesix is an example of a serum-based test used in the clinic that can predict response to a second-line biotherapeutic treatment option.
Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans specific to the patient.
Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.